Holen Sie sich die Stockscreener-App
30.30
0.62%
-0.19
Handel nachbörslich:
30.30
Schlusskurs vom Vortag:
$30.49
Offen:
$30.09
24-Stunden-Volumen:
1.02M
Relative Volume:
0.70
Marktkapitalisierung:
$1.93B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-107.85M
KGV:
-13.71
EPS:
-2.21
Netto-Cashflow:
$-106.82M
1W Leistung:
-1.62%
1M Leistung:
+27.47%
6M Leistung:
+40.93%
1J Leistung:
-28.17%
1-Tages-Spanne:
$29.58
$30.83
1-Wochen-Bereich:
$29.41
$31.80
52-Wochen-Spanne:
$18.53
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Firmenname
Vera Therapeutics Inc
Sektor
Branche
Telefon
650-770-0077
Adresse
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Vergleichen Sie VERA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
30.30 | 1.92B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2025-01-28 | Eingeleitet | Goldman | Buy |
| 2024-11-21 | Eingeleitet | Wells Fargo | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Eingeleitet | Raymond James | Outperform |
| 2023-11-10 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-16 | Eingeleitet | Guggenheim | Buy |
| 2023-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-04 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-19 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
Real time alert setup for Vera Therapeutics Inc. performanceTake Profit & Growth Focused Stock Pick Reports - newser.com
Vera Therapeutics, Inc. (VERA): Investor Outlook on a 109% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Will Vera Therapeutics Inc. stock remain a Wall Street favoriteGold Moves & Weekly Top Gainers Alerts - newser.com
Why Vera Therapeutics Inc. stock could rally in 2025Earnings Overview Summary & Consistent Growth Stock Picks - newser.com
Can Vera Therapeutics Inc. hit a new high this monthBond Market & Consistent Profit Trade Alerts - newser.com
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - MarketScreener
Ranking Vera Therapeutics Inc. among high performing stocks via toolsTrade Entry Summary & Weekly Watchlist of Top Performers - newser.com
Is Vera Therapeutics Inc. stock overvalued by current metricsJuly 2025 Levels & Reliable Breakout Forecasts - newser.com
Vera Therapeutics Inc. stock trend forecastCPI Data & High Return Stock Watch Alerts - newser.com
Is Vera Therapeutics Inc a good long term investmentBear Market Strategies & Follow Top Performers in the Community - earlytimes.in
Vera started at buy by Goldman Sachs, atacicept potential cited - MSN
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Trend analysis for Vera Therapeutics Inc. this weekTrade Risk Report & Community Consensus Stock Picks - newser.com
Detecting support and resistance levels for Vera Therapeutics Inc.2025 Dividend Review & Fast Entry Momentum Alerts - newser.com
Vera Therapeutics' (VERA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Polycythemia Vera Pipeline 2025: FDA Updates, Therapy - openPR.com
What indicators show strength in Vera Therapeutics Inc.Portfolio Gains Summary & Technical Pattern Alert System - newser.com
Using RSI to spot recovery in Vera Therapeutics Inc.2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
Heatmap analysis for Vera Therapeutics Inc. and competitorsBear Alert & AI Powered Buy and Sell Recommendations - newser.com
Risk vs reward if holding onto Vera Therapeutics Inc.2025 Top Gainers & High Accuracy Swing Trade Signals - newser.com
J. Safra Sarasin Holding AG Takes Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Evaluating Vera Therapeutics Inc. with trendline analysisJuly 2025 Outlook & AI Powered Trade Plan Recommendations - newser.com
Developing predictive dashboards with Vera Therapeutics Inc. dataJuly 2025 Snapshot & AI Powered Trade Plan Recommendations - newser.com
What drives Vera Therapeutics Inc stock priceLong-Term Growth Stocks & These Stocks Are Just Getting Started - earlytimes.in
Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $75 - 富途牛牛
Vera Therapeutics, Inc. $VERA Shares Purchased by Platinum Investment Management Ltd. - MarketBeat
13,567 Shares in Vera Therapeutics, Inc. $VERA Acquired by GC Wealth Management RIA LLC - MarketBeat
Fifth Third Bancorp Buys New Stake in Vera Therapeutics, Inc. $VERA - Defense World
10,406 Shares in Vera Therapeutics, Inc. $VERA Purchased by Perigon Wealth Management LLC - MarketBeat
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating - 富途牛牛
What analysts say about Vera Therapeutics Inc stockDividend Reinvestment Plans & Low Risk Investment Tips - earlytimes.in
Vera Therapeutics Inc Stock Analysis and ForecastHigh Beta Stocks & Small Entry Investment Ideas - Early Times
Finanzdaten der Vera Therapeutics Inc-Aktie (VERA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vera Therapeutics Inc-Aktie (VERA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ENRIGHT PATRICK G | Director |
Jun 24 '25 |
Buy |
22.35 |
40,607 |
907,635 |
3,596,593 |
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 21 '25 |
Sale |
27.89 |
10,613 |
296,032 |
213,740 |
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 26 '25 |
Sale |
27.65 |
9,075 |
250,882 |
204,665 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):